India: Are Gene Patents A Hindrance To Innovation?

Last Updated: 26 June 2013
Article by Mrinalini Gupta

Most Read Contributor in India, September 2016

Gene patenting has always been a controversial matter and due to the recent revelation of Angelina Jolie'spreventive double mastectomy, the matter is again in limelight. Much of the ink has been spilt on Gene patenting ever since the issue of patenting of genetically modified organism arose in Diamond v. Chakrabarty, 447 U.S. 303 (1980).

Myriad genetics, a Utah based private biotechnology company, has a monopoly on two genes called BRCA1 and BRCA2. Mutations in these genes can radically raise a woman's chance of developing breast or ovarian cancer. Since Myriad owns the patent rights on these two genes, it is the exclusive provider of the tests related to these genes in United States, thus blocking other diagnostic centres from offering tests based on these genes. Granting monopoly on a DNA sequence through gene patenting has direct impact on various other areas of worldwide medical research such as, drug designing, etc.

The genomics revolution brought about by the genome sequencing and mapping, cloning, selective expression, regulation and silencing of genes, prediction of the three-dimensional structures of a protein etc, has contributed a lot to the rapid development of health care & life sciences. These technologies along with genetic testing to predict a person's predisposition to genetic disorders, have tremendously improved the health care services. Patenting a gene sequence might impede the advancement of genetic testing which helps in detecting the risk of disease before the actual expressing of it. Gene patenting has, therefore, genuinely raised concerns pertaining to the scenario of the genetics research and its possible benefits to health sector.

The Controversy

Patent is granted to an inventor for a limited period of time to encourage him and to have exclusive control over the innovation. While a patent is in force no one is allowed to use it without a license. The major issue in granting patent over a gene sequence is that the sequence normally becomes the property of the company which hinders any further research by another company. Further, from the point of view of a new researcher the increase in the number of gene patents can lead to negotiation of multiple licenses for the advancement of genomic research. Owing to the multiple licenses and royalty payments the cost of research and development is automatically increased. The burden of this increased cost is finally borne by the public.

Another issue which arises in patenting a gene is that they are naturally occurring substances and many countries, including India, bar products of nature from being patented. The thought that a biological material, such as set of genes, existing inside a person's body is owned by someone else is difficult to accept. For this reason, a DNA sequence or a gene is obviously held disqualified from patenting on the grounds that they are discovered and not invented. However, patents are still being granted to a gene sequence on the grounds that they are isolated from their natural environment, purified in vitro and then inventively reconfigured to give rise to a sequence that is new, inventive and has industrial application.

In addition to this, isolation of a specific DNA sequence, mutational analysis and further development of diagnostic methods is an expensive affair which uses huge amount of public funds. Thus, the public may end up paying double the amount- firstly for the research and secondly for high-priced diagnostic methods.

Scenario of Gene Patents under the Indian Patents Act , 1970

According to Section 3(c) of Patents Act, 1970 'the mere discovery of a scientific principle or the formulation of an abstract theory or discovery of any living thing or non living substances occurring in nature' is not considered patentable. Similarly, Section 3(j) renders 'plants and animals in whole or any part thereof other than microorganisms but including seeds, varieties and species and essentially biological processes for production or propagation of plants and animals' not patentable.

Thus, in the light of above mentioned Sections, simply isolating a gene from a living thing amounts to 'discovery' and not 'invention' and hence not patentable. That is to say, under the current Patent regime naturally occurring DNA sequences cannot be patented as such. They can only be patented when after isolating the sequence they are purified and chemically modified resulting into a sequence that is new, inventive and has industrial application.

Further, Section 3(i) says that inventions related to 'any process for the medicinal, surgical, curative, prophylactic, diagnostic therapeutic or other treatment of human beings or any process for a similar treatment of animals to render them free of disease or to increase their economic value or that of their products' are not patentable. That  is, the method of diagnosis practised on the human or animal body are strictly excluded from patenting. However, the diagnostic methods carried out on tissues or fluids, which have been permanently removed from the body fall under the category of patentable inventions provided that they also fulfil the other patentability criteria.

Gene Patents as Gatekeeper patents

Gatekeeper patents are also known as Blocking Patents. It has been defined as "a patent relating to a particular area of technology which prevents another patent from being used because the other patent relies on technology covered by the first."1Genes are an essential element and starting point of many genomic researches. Therefore, if a patent is obtained over a gene, it can hinder the development of potential technologies which might be developed using the basic research technology. The patented basic gene sequence is said to guards the entry of other inventions/gene therapies using that basic sequence. Hence, those patented basic gene sequences are known as gatekeeper patents.

A patent is used as blocking patent by claiming all the essential features of the invention so that no new invention can be invented around it. To invent around it you have to have the license of the blocking patent.

In genomic research and diagnostics, having a patent over a gene sequence or a part of it can be regarded to obstruct the further development of genetic tests as it is impossible to devise an alternative way of testing the disease without using that patented gene sequence or a part of it. For instance, Human Genome Sciences Inc. (HGS), a biopharmaceutical company, obtained patent over a human gene CCR5 that was later identified to have key role in HIV infection. When the company filed the patent application for CCR5 in 1995, it had no clue that there was a link to AIDS. Later, when it was discovered by the scientists across the world that CCR5, a cell surface receptor, is used by Human Immunodeficiency Virus (HIV) to gain entry to a cell it was extensively feared that this patent would act as gatekeeper and would block further research on AIDS. However, HGS did not prevent scholars from undertaking unlicensed research on CCR5. On the other hand, if HGS had taken a contrary decision, it would have had created a calamitous impact on AIDS research.


A gene, though being a natural substance, qualifies the patentability criteria on the basis that are isolated from the body, purified in vitro and then inventively reconfigured to give rise to a sequence that is new, inventive and has industrial application.

The patent regime confers exclusive right upon the holder of the patent to make, use and sell that invention for a period of twenty years. As it is practically not possible for an individual to enlist all the mutations and potential gene therapies based on them at once, it can therefore be concluded that the monopoly granted to a patent holder over a gene sequence can exorbitantly elevate the costs of genomic research and further development of new gene therapies.



The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.